Nonalcoholic fatty liver disease: Hepatic manifestation of obesity and the metabolic syndrome

Postgraduate Medicine

Volumn 120, Issue 2, 2008, Pages

  Boppidi, Hima ^a,b   Daram, Sumanth R ^b  

^a OSMANIA MEDICAL COLLEGE   (India)

^b Wheaton Franciscan Healthcare St Joseph's Hospital   (United States)

Author keywords

Metabolic syndrome; MetS; NAFLD; NASH; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Obesity

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; ATORVASTATIN; BETAINE; GEMFIBROZIL; LOSARTAN; METFORMIN; PENTOXIFYLLINE; PLACEBO; PROBUCOL; SIBUTRAMINE; TETRAHYDROLIPSTATIN; URSODEOXYCHOLIC ACID;

ABDOMINAL RADIOGRAPHY; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DYSLIPIDEMIA; HUMAN; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIVER FAILURE; LIVER FIBROSIS; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PATHOLOGY; PATHOPHYSIOLOGY; PREVALENCE; PUBLIC HEALTH; REVIEW; STOMACH BYPASS; ALGORITHM; DECISION TREE; FATTY LIVER;

ALGORITHMS; DECISION TREES; FATTY LIVER; HUMANS; METABOLIC SYNDROME X; OBESITY;

EID: 54049091645     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2008.07.1800     Document Type: Review

References (62)

1. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003;37(5):1202-1219. (Pubitemid 36538699)
2. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis. 2001;21(1):3-16. (Pubitemid 32240482)
3. Liou I, Kowdley KV. Natural history of nonalcoholic steatohepatitis. J Clin Gastroenterol. 2006;40(3 suppl 1):S11-S16. (Pubitemid 44309538)
4. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846-854. (Pubitemid 46631552)
5. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet. 2005;366(9491):1059-1062. (Pubitemid 41338752)
6. Lonardo A, Lombardini S, Ricchi M, et al. Review article: hepatic steatosis and insulin resistance. Aliment Pharmacol Ther. 2005;22(suppl 2):64-70. (Pubitemid 41564387)
7. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98(5):960-967. (Pubitemid 36733754)
8. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatoiogy. 2004;40(6):1387-1395. (Pubitemid 39657013)
9. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology. 2005;42(1):44-52. (Pubitemid 40911310)
10. Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000;132(2):112-117. (Pubitemid 30044177)
11. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology. 1990;12(5):1106-1110.
12. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Non-alcoholic steatohepatitis: an expanded clinical entity. Gastroenterology. 1994;107(4):1103-1109. (Pubitemid 24294573)
13. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40(6):1387-1395. (Pubitemid 39657013)
14. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology. 1990;11(1):74-80. (Pubitemid 20075105)
15. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999;30(6):1356-1362.
16. Diehl AM, Goodman Z, Ishak KG. Alcohollike liver disease in non-alcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology. 1988;95(4):1056-1062. (Pubitemid 18235552)
17. Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol. 1989;20(6):594-598. (Pubitemid 19164370)
18. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology. 1998;114(4):842-845.
19. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112(12):1796-1808. (Pubitemid 38063703)
20. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-nlpha or adiponectin? Hepatology. 2004;40(1):46-54. (Pubitemid 38868922)
21. Saxena NK, Ikeda K, Rockey DC, Friedman SL, Anania FA. Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology. 2002;35(4):762-771. (Pubitemid 34258369)
22. Bataller R, Schwabe RF, Choi YH, et al. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest. 2003;112(9):1383-1394. (Pubitemid 38057692)
23. Oben JA, Roskams T, Yang S, et al. Norepinephrine induces hepatic fibrogenesis in leptin deficient ob/ob mice. Biochem Biophys Res Commun. 2003;308(2):284-292. (Pubitemid 36937177)
24. Paradis V, Perlemuter G, Bonvoust F, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology. 2001;34(4 Pt 1):738-744. (Pubitemid 32927998)
25. Zandbergen AA, Lamberts SW, Janssen JA, Bootsma AH. Short-term administration of an angiotensin-receptor antagonist in patients with impaired fasting glucose improves insulin sensitivity and increases free IGF-I. Eur J Endocrinol. 2006;155(2):293-296. (Pubitemid 44269446)
26. Jin HM, Pan Y. Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy. Nephrol Dial Transplant. 2007;22(7):1943-11049 (Pubitemid 47244764)
27. Harrison SA, Di Bisceglie AM. Advances in the understanding and treatment of nonalcoholic fatty liver disease. Drugs. 2003;63(22):2379-2394. (Pubitemid 37392905)
28. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116(6):1413-1419. (Pubitemid 29258890)
29. Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol. 1989;20(6):594-598. (Pubitemid 19164370)
30. Cortez-Pinto H, Baptista A, Camilo ME, Dc Moura MC. Nonalcoholic steatohepatitis - a long-term follow-up study: comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci. 2003;48(10):1909-1913. (Pubitemid 37419951)
31. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129(1):113-121. (Pubitemid 41002048)
32. Evans CD, Oien KA, MacSween RN, Mills PR. Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury? J Clin Pathol. 2002;55(9):689-692. (Pubitemid 34970092)
33. Harrison SA, Torgerson S, Hayashi PH. The natural history of non-alcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol. 2003;98(9):2042-2047. (Pubitemid 37185803)
34. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol. 2005;42(1):132-138. (Pubitemid 40038911)
35. Kim WR, Poterucha JJ, Porayko MK, Dickson ER, Steers JL, Wiesner RH. Recurrence of nonalcoholic steatohepatitis following liver transplantation. Transplantation. 1996;62(12):1802-1805. (Pubitemid 27014542)
36. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123(3):745-750. (Pubitemid 34977081)
37. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346(16):1221-1231.
38. Sanyal AJ. American Gastroenterological Association. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002;123(5):1705-1725.
39. Park SH. Nonalcoholic steatohepatitis: pathogenesis and treatment. Korean J Hepatol. 2008;14(1):12-27.
40. Okita M, Hayashi M, Sasagawa T, et al. Effect of moderately energy-restricted diet on obese patients with fatty liver. Nutrition 2001;17(7-8):542-547. (Pubitemid 32633783)
41. Neuschwander-Tetri BA, Bacon BR. Non-alcoholic steatohepatitis. Med Clin North Am. 1996;80(5):1147-1166.
42. Harrison SA, Fincke C, Helinski D, Torgerson S, Hayashi P. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther. 2004;20(6):623-628. (Pubitemid 39279050)
43. Sabuncu T, Nazligul Y, Karaoglanoglu M, Ucar E, Kilic FB. The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. Rom J Gastroenterol. 2003;12(3):189-192. (Pubitemid 37152602)
44. Clark JM, Alkhuraishi AR, Solga SF, Alli P, Diehl AM, Magnuson TH. Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease. Obes Res. 2005;13(7):1180-1186.
45. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116(6):1413-1419. (Pubitemid 29258890)
46. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology. 2003;38(4):1008-1017. (Pubitemid 37221684)
47. Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology. 2004;39(1):188-196. (Pubitemid 38461481)
48. Reynaert H, Geerts A, Henrion J. Review article: the treatment of non-alcoholic steatohepatitis with thiazolidinediones. Aliment Pharmacol Ther. 2005;22(10):897-905. (Pubitemid 41634870)
49. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;38(24):1008-1017.
50. Uygun A, Kadayifci A, Isik AT, et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2004;19(5):537-544. (Pubitemid 38387180)
51. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis, J Hepatol. 1999;31(2):384. (Pubitemid 29349772)
52. Horlander JC, Kwo PY, Cummings OW, et al. Atorvastatin for the treatment of NASH [abstract]. Gastroenterology. 2001;120:A544.
53. Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol. 2001;96(9):2711-2717. (Pubitemid 32889210)
54. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr. 2000;136(6):734-738. (Pubitemid 30415645)
55. Merat S, Malekzadeh R, Sohrabi MR, et al. Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study. J Hepatol. 2003;38(4):414-418. (Pubitemid 36399242)
56. Adams LA, Zein CO, Angulo P, et al. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol. 2004;99(12):2365-2368. (Pubitemid 40039367)
57. Lindor KD, Kowdley KV, Heathcote EJ, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology. 2004;39(3):770-778. (Pubitemid 38337657)
58. Yokohama S, Tokusashi Y, Nakamura K, et al. Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis. World J Gastroenterol. 2006;12(2):322-326. (Pubitemid 43336936)
59. Contos MJ, Cales W, Sterling RK, et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl. 2001;7(4):363-373. (Pubitemid 32331542)
60. Thuluvath PJ. Morbid obesity with one or more other serious comorbidities should be a contraindication for liver transplantation. Liver Transpl. 2007;13(12):1627-1629.
61. Clark JM, Diehl AM. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA. 2003;289:3000-3004. (Pubitemid 37430103)
62. Charlton M, Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol. 2004;2(12):1048-1058. (Pubitemid 40037633)